natgillin/translations-raw huggingface dataset:
testing the desired physico-chemical characteristic(s) of the precipitated solid ligand-modified poly oxo-hydroxy metal ion material; and 
ispitivanje željenih fizikalno-kemijskih karakteristika od nataloženog krutog materijala poli-okso-hidroksi-metalnih iona modificiranog ligandima; i
One day after the last administration autopsy is performed and the right femur is dissected out. 
Dan nakon posljednje primjene provedena je autopsija, te je provedena disekcija desne butne kosti.
Next, the capsule has to be opened or perforated with pins or cutting blades in order to allow part of the inspiratory air stream to pass through the capsule for powder entrainment or to discharge the powder from the capsule through these perforations by means of centrifugal force during inhalation. 
Zatim se kapsula treba otvoriti ili probušiti iglom ili odrezati sječivom kako bi se omogućio prolaz zračnoj struji udisaja kroz kapsulu i povlačenje praška, odnosno za pražnjenje praška iz kapsule kroz navedene perforacije uslijed centrifugalne sile tijekom inhalacije.
A demountable pole dancing stage comprising a substantially cylindrical central hub, which has a vertically extending central axis and is adapted to support a vertically extending pole, a plurality of radially outwardly extending support members mounted to the hub and a stage platform, wherein the stage platform comprises a plurality of segments adapted to be supported on the support members, wherein, when the demountable pole dancing stage is in an assembled state, the hub is arranged to support the vertically extending pole at a first end, to support a person pole dancing on the vertically extending pole. 
Sklopiva pozornica za ples na šipki koja se sastoji od cilindričnog središta koje ima okomitu središnju os i izrađeno je kao nosač ravno uzdignute šipke, od više radijalno raspoređenih nosivih elemenata montiranih na središte i od podija, pri čemu se podij sastoji od više segmenata koji su prilagođeni za montiranje na nosive elemente, pri čemu, kad je sklopiva pozornica za ples na šipki rasklopljena, središte nosi ravno uzdignutu šipku i osobu koja pleše na toj šipki.
The compound or therapeutically acceptable salt of claim 1 or 3, wherein 
(IIla) . ili njegova terapeutski prihvatljiva sol pri čemu
Door closer according to the preceding claim, wherein said at least one first front face (35", 36") and at least one first contact surface (37", 38") are substantially parallel to each other in said closed door position and substantially perpendicular to each other in said open door position, said at least one second front face (45") and at least one second contact surface (46") being substantially perpendicular to each other in said closed door position and substantially parallel to each other in said open door position. 
Spojnica za zatvaranje vrata prema zahtjevu 5, gdje su to barem jedno prvo prednje lice (35", 36") i barem jedna prva kontaktna površina (37", 38") u biti međusobno paralelni u zatvorenom položaju vrata i u biti međusobno okomiti u položaju otvorenih vrata, barem jedno drugo prednje lice (45") i barem jedna druga kontaktna površina (46") su u biti međusobno okomiti u zatvorenom položaju vrata 1 u biti međusobno paralelni u položaju otvorenih vrata.
Said equipment for UV radiation or infrared radiation is arranged such in order to pre-dry the before planned surface of the respective pieces of wood 10 at its surface. 
Navedena oprema za UV zračenje ili infra-crveno zračenje je postavljena s namjerom da izvrši pred-sušenje prije izravnane površine odgovarajućih komada od drva 10 na njihovim površinama.
The beverage production device can comprise control means and valve means configured for selectively supplying the common hot water outlet with hot water simultaneously from the two thermoblocks when none of the brewing chambers are supplied with hot water from any of the thermoblocks. 
Naprava za proizvodnju napitaka može sadržavati i sustav za kontrolu, te ventile podešene za selektivno dovođenje vruće vode na zajednički izlaz za vruću vodu istodobno iz dva termobloka kada se niti u jednu od komora za kuhanje ne dovodi vruća voda iz bilo kojeg od termoblokova.
encoding at least one isolated IL-23p19 antibody according to any of claims 1-4; or 
(a) kodira najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2;
The gear box 14 drives a spindle 15, which cooperates with a shaft having two shaft guidances 18. 
Zupčani prijenosnik 14 drži u pogonu vreteno 15 koje je u radu povezano s osovinom koja ima dvije vodilice osovine 18.
A seventh process (G) according to the invention comprises carrying out a process selected from processes (A) to (F) followed by interconversion of one or more functional groups. 
Treći postupak (C) sastoji se u provedbi postupka kojeg sc bira između postupaka (A) i (B), uz naknadnu interkonverziju jedne ili više funkcionalnih skupina.
The method of item 54, wherein the step is repeated until the codon pair bias is reduced by a desired amount. The method of item 54, wherein the step is repeated until the codon pair bias converges on or near an optimal value. 
Postupak prema zahtjevu 24., naznačen time što a) = korak se ponavlja sve dok se pristranost para kodona ne smanji za željenu količinu, ili b) - korak se ponavlja sve dok ne konvergira pristranost parova kodona.
A compound of formula or a pharmaceutical salt thereof. 
(OD U ili njegova farmaceutska sol. .
of 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less. 
5% ili manji, 4% ili manji, 3% ili manji, 2% ili manji, 1% ili manji.
wherein R′ and R″ independently represent one, two or three hydrogen, halogen, or C1-6-alkyl and L represents a leaving group is reacted with a metallation agent selected from alkyl lithium, alkyl magnesium or magnesium and an optionally substituted N-benzyl-4-piperidone 
an pri čemu R* i R" nezavisno predstavljaju jedan, dva ili tri vodika, halogen, C,.g-alkil ili C,.g-alkilen i L predstavlja odlazeću skupinu, reagira sa sredstvom za dodavanje atoma metala izabranim između alkil litija, alkil magnezija ili magnezija i N-benzil-4-piperidonom koji može biti po izboru supstituiran
The combination product according to any one of claims 1 to 3, wherein said acetylcholinesterase inhibitor (AChEI) is galantamine or a pharmaceutical salt thereof. 
Kombinacijski produkt prema patentnom zahtjevu 1 do 3, naznačeno time da rečeno sredstvo koje blokira koneksin jest meflokvin.
The electromagnetic relay assembly of claim 1 wherein the first and second spring arms (15) are parallel and comprise opposed arm faces (40), the opposed arm faces (40) being magnetically attracted to one another during a short circuit scenario, the magnetically attracted arm faces (40) for maintaining the switch assembly in the closed position during the short circuit scenario. 
Elektromagnetski relejni sklop u skladu s patentnim zahtjevom 1, naznačen time što su krakovi opruge međusobno paralelni bilo u otvorenom ili u zatvorenom položaju i svaki od njih sadrži nasuprotno postavljene površine, gdje se nasuprotno postavljene površine međusobno magnetski privlače u slučaju kratkog spoja, gdje magnetski privučene površine održavaju kontakte u zatvorenom položaju u slučaju kratkog spoja.
at least 1 % by weight of a vegetable or animal oil with a melting point below 20 °C; 
najmanje 1%, težinski, biljnog ili životinjskog ulja s talištem ispod 20 "€; ii.
The unit 50 enters the normal mode of acquiring amplifier 90 output voltage 90u: the absolute value of the difference between the sampled output voltage 90u of amplifier 90 and the zero-reference value stored in phase III, is calculated. 
Jedinica 50 prelazi u normalni način uzimanja izlaznog napona 90u pojačala 90: računa se apsolutna vrijednost razlike između uzorkovanog izlaznog napona i nulte reference koja je spremljena u fazi III.
The process of claim 1, wherein the second acid is an inorganic acid. 
Postupak prema patentnom zahtjevu 2, pri čemu je kiselina u koraku vc, neorganska kiselina.
The paper product of claim 1, wherein the coating comprises at least about 25 wt. % of the co-processed microfibrillated cellulose and inorganic particulate material composition. 
Papirni proizvod, koji sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala, naznačen time što papirni proizvod ima:
2. The pharmaceutical composition as claimed in either claim 1 or 2, which may be used for the treatment of cancer. The pharmaceutical composition as claimed in claim 9, wherein the cancer is a lung tumor, a breast tumor, a prostate tumor, a melanoma, a colon tumor, a gastric tumor, a pancreatic tumor, an ENT tumor, a renal cell carcinoma or a cervical carcinoma, a colon carcinoma or a mammary carcinoma. 
Farmaceutska kompozicija za primjenu prema zahtjevu 1, gdje je terapeutska metoda metoda liječenja ili prevencije raka, naznačeno time da je ekspresija antigena povezanog s tumorom prema zahtjevu 1, pri čemu je rak tumor jednjaka, tumor jajnika, tumor glave-vrata, tumor bubrega, tumor jetre, tumor pluća, tumor dojke, tumor prostate, tumor kolona, tumor želuca, rak želuca, tumor pankreasa, karcinom bubrežnih ćelija, karcinom kolona ili karcinom mliječnih žlijezda.
The oligomer according to any one of claims 1 to 3, wherein the nucleic acid target is selected from the group consisting of ApoB, PCSK9, miR-122, FVII, FXI, ApoCII, Apo(a), HBV, ANGPTL3, GCGR, FGFR4, DGAT-2, GCCR, Complement component C5, AAT, TTR, ALAS-1, and VEGF . 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da je ciljna nukleinska kiselina odabrana iz skupine koja se sastoji od mikroRNK, mRNK, lncRNK (duge nekodirajuće RNK), snRNK, snoRNK te virusne RNK.
A compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof: 
Spoj predstavljen sa slijedećom formulom (I) ili njegova farmaceutski prihvatljiva kisela adicijska sol:
In accordance with a first aspect of the present invention, there is provided a delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at about pH 6.5 or above, and wherein the inner layer comprises a third polymeric material that is soluble in intestinal fluid, said third polymeric material being a polycarboxylic acid polymer that is at least partially neutralised, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions. 
HR P20180965 T1 PATENTNI ZAHTJEVI Formulacija lijeka s produženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo pacijenta, pri čemu spomenuti pripravak sadrži: jezgro i prevlaku za jezgru, to jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski sloj i unutarnji sloj; pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.
Loading of the Ladder and the Sample: 
Broj objave europskog patenta:
The flexible containers usually include a flexible pouch, often made of polyethylene, and include a spout through which the contents of the pouch can flow. 
Općenito, ovi fleksibilni spremnici imaju vrećicu koja je normalno načinjena od polietilena (PE) i kljun koji omogućava da se proizvod koji se nalazi u spremniku može istočiti.
obtaining cellulosic staple fibres or filament; 
(1) dobivanje celuloznih štapel vlakana ili filamenta;
VLAN Virtual LAN A method for data processing in a communication network, 
Postupak za obradu podataka, provodi ga mrežni čvor u komunikacijskoj mreži,
The selectivity of HI resins depends on the structure of the hydrophobic ligand. 
Selektivnost smola za HI ovisi o strukturi hodrofobnog liganda.
The mixture can also comprise other substances such as colorants, stabilizers or the like. 
Ova mješavina može također sadržavati druge supstance kao što su sredstva za bojanje, sredstva za stabiliziranje ili tome slično.
-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide: or a pharmaceutically acceptable salt thereof, and wherein said granule further comprises a surfactant, and wherein said pharmaceutical composition comprises a lubricant, and the concentration of said lubricant does not exceed 1% by weight of the pharmaceutical composition. 
HR P20151383 T1 HR P20151383 T1 PATENTNI ZAHTJEVI mne ili njegova farmaceutski prikladna sol, i gdje te granule dalje sadrže surfaktant, i gdje taj farmaceutski pripravak sadrži lubrikant, i koncentracija tog lubrikanta ne prelazi 1% težine farmaceutskog pripravka.
(M1-2) R-Imazamox + Metazachlor (monoclinic or triclinic or any mixture of those) (M4) Imazamox + Metazachlor (monoclinic or triclinic or any mixture of those) + clomazone 
(M4) Imazamoks + Metazaklor (monoklinasta ili troklinasta ili bilo koja njihova smjesa) + klomazon (M4-1) R-Imazamoks + Metazaklor koja sadrži najmanje 90% mase monoklinastog oblika + klomazon
Use of a phosphate buffer system has been found to be particularly effective in providing long-term stability in lozenge pH. 
Utvrđeno je da je uporaba fosfatnog puferskog sustava posebno efikasna u osiguravanju dugotrajne stabilnosti pH tablete.
is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, aryl or substituted aryl, alkylaryl or substituted alkylaryl; optionally, R4 and R5 may be combined to form alkenyl or substituted alkenyl; 
je vodik, alkil ili supstituirani alkil, cikloalkil ili supstituirani cikloalkil, aril ili supstituirani aril, alkilaril ili supstituirani alkilaril; po izboru, R4 i R5 mogu biti spojeni da formiraju alkenil ili supstituirani alkenil;
In an embodiment, the mobile communication technology is one out of the following: 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je mobilna komunikacijska tehnologija jedna od slijedećih:
A compound of Formula I: or pharmaceutical salt, enantiomer, hydrate, solvate, or tautomer thereof, wherein: 
Farmaceutski sastav koji sadrži spoj formule I-13 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač:
Process of claim 1 or 2 characterized in that sound, ultrasound, in an interval of one MHz, mechanical stir or magnetic fields are usable for giving energy to the process. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da se za davanje energije tom postupku mogu upotrebljavati zvuk, ultrazvuk, u intervalu od jednog MHz, mehaničko pokretanje ili magnetska polja.
The device of claim 1, further comprising a safety pressure outlet to relieve pressure from said chamber when said pressure exceeds a predefined pressure level. 
Sustav prema zahtjevu 1, naznačen time, da nadalje sadrži sigurnosni izlazni tlak (20D) za oslobađanje tlaka iz navedene komore kada navedeni tlak prelazi unaprijed definiranu razinu tlaka.
Preferred component B) comprises Metazachlor, in particular monoclinic Metazachlor. 
Poželjna komponenta _B) sadrži metazaklor, posebno monoklinasti metazaklor, dimetenamid, dimetenamid-P, metolaklor i quinmerac.
A drop resistive-capacitive network 46, shown inside dashed line, is connected to conductor 45 to reach a rectifying bridge 47 which is directly connected to the power network 10 via conductor 44. 
Stabilna kapacitivna mreža 46, prikazana u crtkanom okviru, je spojena na vodič 45 kojim se dolazi do ispravljačkog mosta 47 koji je direktno spojen na električnu mrežu 10 pomoću vodiča 44.
Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indo-3-yl or indol-5-yl, and is hydrogen, methyl, or 2-hydroxy-ethyl, or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which 
Har1 je piridin-3-il, piridin-4-il, indol-2-1l, indol-3-11 ili indol-5-il, i R612 je vodik, metil ili 2-hidroksietil, ili R611 i R612, zajedno s i uključivši atom dušika na kojeg su vezani, tvore heterociklički prsten Hetl, gdje
are 9 to 30, 9 to 20 or 13 to 17 amino acids in length; and/or 
da je manje od 5% rečenog peptida nazočno u dimeričkom obliku u otopini; i/ili
valve means comprising at least one shut-off member and located in the axial conduit to block the drilling mud and stop a flow of the drilling mud from the upstream end to the downstream end; 
– ventilno sredstvo (6), koje ima najmanje jedan zatvarački element i koje se nalazi u navedenom aksijalnom vodu radi blokiranja navedene isplake i zaustavljanja njezinog protoka od navedenog uzvodnog kraja (2a) do navedenog nizvodnog kraja (2b);
The hydrogen pressure is adjusted to 0.5 MPa. 
Tlak vodika se podesi na 0,5 MPa.
The method according to claim 4, further comprising a dispensing start step and a plate knitting dispensing step, during said plate knitting dispensing step said dispensing end of the body of the second yarn finger being moved, with respect to its position during said dispensing start step, along said direction in accordance with the direction of rotation of the needle cylinder with respect to said feed. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time, da obuhvaća početni korak distribucije 1 korak distribucije platirnog pletiva, za vrijeme navedenog koraka distribucije platirnog pletiva, navedeni kraj (12) za distribuciju tijela drugog vodiča za predivo (8) se pomiče u odnosu na svoj položaj tijekom navedenog koraka početka distribucije, duž navedenog smjera (14) u skladu sa smjerom okretanja cilindra s iglama (2, 3) u odnosu na navedeni dovod.
The pharmaceutical composition for use as claimed in Claim 2, comprising about 85 wt% to about 99.5 wt% of hyaluronic acid and about 0.5 wt% to about 15 wt% of the HMG-CoA reductase inhibitor, based on the total weight of hyaluronic acid and the HMG-CoA reductase inhibitor. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da obuhvaća hijaluronsku kiselinu od oko 85 masenih % do oko 99,5 masenih % i inhibitor reduktaze HMG-CoA od oko 0,5 masenih % do oko 15 masenih %, na temelju ukupne mase hijaluronske kiseline i inhibitora reduktaze HMG-CoA.
When the handle 25 is in the upright position, the cam 56 pushes the operating fork 23 downwards against the spring pressure of springs 59, 60, so that the sleeve 20 is placed in its lowermost position and the ball 22 rests on the valve seat under the influence of gravity and forms a liquid-tight seal. 
Kad je ručka 25 u gornjem položaju, bregasta osovina 56 pritišće radnu vilicu 23 prema dolje suprotno pritisku opruga 59, 60 tako da je rukavac 20 postavljen na svoj krajnji donji položaj i kugla 22 počiva na ležištu ventila pod utjecajem gravitacije i tako čini nepropusnu brtvu.
Stirring was continued for 2 hours, the crystals were collected and washed twice with 3.5 L of cold (-10 °C) ethanol. 
Miješanje je nastavljeno tijekom 2 sata, kristali su prikupljeni i isprani dvaput s 3,5 L hladnog (- 10 *C).
the heavy chain variable domain is SEQ ID NO:75 and the light chain variable domain is SEQ ID NO:76; 
varijabilna domena jakog lanca je SEQ ID NO:39 i varijabilna domena slabog lanca je SEQ ID NO:40, ili
determining, by the user terminal based on the uplink resource index, the first group of the at least one uplink subframe in the uplink subframe set. 
Postupak prema zahtjevu 1, naznačen time da se nadalje sastoji od: primanja, na korisničkom terminalu, odobrenja uzlazne veze koje prenosi indeks resursa za uzlaznu vezu;
Compounds of formula (I) may be prepared by reaction of the carboxylic acid (11, wherein R1, R2 and R3 have the meanings defined in formula 1). 
Spojeve formule (1) može se dobiti reakcijom karboksilne kiseline (11), gdje Ri, R2 i Rz znače kao što je definirano za formulu (1)
compressing the blend from the step (5) into a tablet; and 
komprimiranje smjese iz (5) u tablete;
The pharmaceutical composition of claim 9, wherein the herpes simplex virus gene is selected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, and UL55. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je inaktivirajuća mutacija u najmanje jednom genu virusa herpes simplex kojeg se bira iz skupine koju čine ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, te UL55.
The ultrafilter was sanitizised by filtering 500 mL of 0.5 M NaOH, for not less than 30 minutes and following washing of the ultrafilter with purified water until the pH permeate was below 7.5. 
Ultrafilter se bio steriliziran filtriranjem s 500 mL 0.5 M NaOH u trajanju od najmanje 30 min nakon čega slijedi ispiranje ultrafiltera s pročišćenom vodom sve dok pH permeata nije pao ispod 7.5.
After inhalation, the emptied capsule has to be removed from the inhaler again. 
Nakon inhalacije, ispražnjena kapsula se vadi iz inhalatora.
The binding molecule of claim 9, wherein the binding domain is selected from the binding site of an antibody; an enzyme; a hormone; a receptor; a cytokine; an immune cell surface antigen; a ligand and an adhesion molecule, wherein the molecule optionally exhibits avidity. 
Vezujuća molekula iz zahtjeva 9, gdje je vezujuća domena odabrana od vezujućeg dijela antitijela; enzima; hormona; receptora; citokina; antigen sa površine imunih stanica; liganda i adhezijske molekule, gdje molekula opcionalno pokazuje afinitet.
Table 1: Known endoglucanases of the GH7 class 
Datum podnošenja europske prijave patenta:
The article of manufacture according to item 14, wherein the container comprising the stable freeze-dried formulation and the one comprising a solvent for reconstitution are the two compartments of a dual-chamber system. 
Proizvodni artikl prema zahtjevu 11, naznačen time da spremnik koji sadrži stabilnu liofiliziranu formulaciju i onaj koji sadrži otapalo za rekonstituciju su dva odjeljka sustava sa dvije komore.
a mechanical treatment comprising subjection to a volumetric power input of 1-500 kW/m3 for a duration of 0.1-60 min; and/or 
mehaničke obrade koja se sastoji od podvrgavanja volumetrijskom dovodu snage od 1-500 kW/m3 tijekom 0.1-60 minuta; i/ili (ii)
Use according to claim 2 characterized in that the daily dosage for tramadol is between 50 and 400 mg/day and that the daily dosage of flupirtine is between 100 to 800 mg/day. 
Uporaba u skladu s patentnim zahtjevom 2, naznačena time, da je dnevna doza tramadola u rasponu od 50 do 400 mg/dan, a dnevna doza flupirtina je u rasponu od 100 do 800 mg/dan.
said monoclonal antibody is an anti-EGFR monoclonal antibody when the subject has EGFR-expressing, metastatic colorectal carcinoma, EGFR-expressing head and neck cancer or KRAS mutant cancer. 
(iii) je spomenuto monoklonsko protutijelo anti-EGFR monoklonsko protutijelo kada subjekt ima s EGFR povezanu ekspresiju, metastazni kolorektalni karcinom, s ekspresijom EGFR povezanu karcinom glave i vrata ili KRAS mutant karcinom.
A method as recited in claim 1, wherein said subject is a subject suffering from pain selected from the group consisting of postoperative pain, inflammatory pain, migraine pain, headache pain, irritable bowel syndrome pain, fibromyalgia pain, arthritic pain, skeletal pain, joint pain, gastrointestinal pain, muscle pain, angina pain, facial pain, pelvic pain, claudication, post traumatic pain, tension headache pain, obstetric pain, gynecological pain, and chemotherapy-induced pain. 
Tapentadol za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je bol izabrana iz grupe koja se sastoji od postoperativne boli, upalne boli, boli povezane s migrenom, boli povezane s glavoboljom, boli povezane sa sindromom iritabilnog crijeva, boli povezane s fibromialgijom, artritične boli, koštane boli, boli u zglobovima, gastrointestinalne boli, mišićne boli, boli uslijed angine, boli u licu, boli u zdjelici, klaudikacije, postoperativne boli, posttraumatske boli, tenzijske glavobolje, opstetričke boli, ginekološke boli, i boli inducirane kemoterapijom.